Vincent Wai-Sun Wong
Hepatology — Prince of Wales Hospital (China), China
Vincent Wai-Sun Wong
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Pharmacy - Public Health
Main Topics
Publications and Clinical Studies
Organizations
Prince of Wales Hospital (China) -
Publications Synthesis
Source: Pubmed
Number : 957
Citations
Main journals
Best Journals
Breakdown by type
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis. liver diseases, diabetes mellitus, mortality, binge drinking, public health, liver, prevalence, risk factors, gastrointestinal diseases, drinking, mortality, premature, alcohol drinking, diabetes mellitus, type 2 | Lancet Gastroenterol Hepatol Top journal | 2026 | 0 |
| Lifespan approaches for the prevention and management of steatotic liver disease. liver diseases, liver, therapeutics | Nat Rev Gastroenterol Hepatol Top journal | 2026 | 0 |
| Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes. diabetes mellitus, carcinoma, hepatocellular, gastroenterology, fibrosis, classification, biopsy, liver, diabetes mellitus, type 2 | Gut | 2026 | 0 |
| Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. liver diseases, gastroenterology, liver | Gastroenterology | 2026 | 0 |
| Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement. liver diseases, gastroenterology, neoplasms, liver, colorectal neoplasms | Gut | 2026 | 0 |
Clinical Studies 32
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors NCT06549673 — research design, hypertension, safety, fibrosis, hepatitis, chronic, liver, esophageal and gastric varices, endoscopy, hypertension, portal, varicose veins, hepatitis | N/A | Recruiting | 2025 |
| Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects NCT07024212 — liver diseases, injections, safety, fibrosis, pharmaceutical preparations, non-alcoholic fatty liver disease, liver, alcoholics, fatty liver, fatty liver, alcoholic | Phase 2 | Active not recruiting | 2025 |
| Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter NCT06203548 — liver diseases, exercise, portion size, life style, eating, fibrosis, non-alcoholic fatty liver disease, liver, biomarkers, alcoholics, energy intake, body weight, resistance training, meals, fatty liver, fatty liver, alcoholic, dietary patterns | N/A | Recruiting | 2024 |
| Risk Factors for Hepatic Inflammation Fibrosis and Prognosis in Patients With CHB and NAFLD NCT05766449 — liver diseases, diabetes mellitus, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, neoplasms, hepatitis, chronic, liver, alcoholics, liver neoplasms, hepatitis a, risk factors, hepatitis b, fatty liver, fatty liver, alcoholic, prognosis, hepatitis b, chronic, hepatitis | N/A | Recruiting | 2022 |
| The Effect of Monitoring PVP on Clinical Outcomes in Patients With PH NCT04820166 — hypertension, portal pressure, venous pressure, hypertension, portal, diagnosis, therapeutics | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map